Pulsed introduction of low-dose RANKL as a therapy for osteogenesis imperfecta
US10111928B1 · kind B1 · utility
1Cited by
1References
7Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Sep 14, 2016 |
| Grant date | Oct 30, 2018 |
| Priority date | — |
| Expiry date | Sep 14, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/177
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Systems and methods for treating osteogenesis imperfecta using FoxP3+ CD8 T-cells (TcREG). Osteoclasts are induced to produce FoxP3+ CD8 T-cells (TcREG) through introduction of a low-dose of a RANK agonist such as RANKL. The RANKL was found to best work when provided in accordance with a schedule resulting in a pulsed administration.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.